{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T15:15:44Z","timestamp":1770995744927,"version":"3.50.1"},"reference-count":16,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,3,22]],"date-time":"2011-03-22T00:00:00Z","timestamp":1300752000000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Off\u2010label use of lenalidomide (Len) in chronic lymphocytic leukemia (CLL) is becoming increasingly frequent. When compared with thalidomide, Len has been reported to have more potent anti\u2010tumour activity and a better safety profile. However, dermatological side\u2010effects are known to occur with both drugs. Clinical trial design often precludes precise quantification of infrequent toxicities and studies frequently report only grade 3\u20134 toxicities without a detailed description of rashes, leading to under\u2010recognition of these complications in the community. Careful long\u2010term tracking of late adverse effects with prompt reporting on recognition is imperative while monitoring patients for potential adverse events as we enter the new era of targeted therapies. We present an unusual case of CLL that was complicated by erythema annulare centrifugum and neutrophilic dermatosis (Sweet's syndrome) after starting Len.<\/jats:p>","DOI":"10.1111\/j.1445-5994.2011.02426.x","type":"journal-article","created":{"date-parts":[[2011,3,23]],"date-time":"2011-03-23T01:58:08Z","timestamp":1300845488000},"page":"286-288","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dermatological complications following initiation of lenalidomide in a patient with chronic lymphocytic leukaemia"],"prefix":"10.1111","volume":"41","author":[{"given":"N.","family":"Tageja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Giorgadze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Zonder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,3,22]]},"reference":[{"key":"e_1_2_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2008.03859.x"},{"key":"e_1_2_2_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08125.x"},{"key":"e_1_2_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08132.x"},{"key":"e_1_2_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_2_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.12.041"},{"key":"e_1_2_2_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.8.1070-b"},{"key":"e_1_2_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.12.011"},{"key":"e_1_2_2_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.10.1298"},{"key":"e_1_2_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb03083.x"},{"key":"e_1_2_2_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-2-36"},{"key":"e_1_2_2_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.9709"},{"key":"e_1_2_2_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.0401"},{"key":"e_1_2_2_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-130120"},{"key":"e_1_2_2_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21571"},{"key":"e_1_2_2_16_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.005835"},{"key":"e_1_2_2_17_2","unstructured":"[cited 2011 Mar 7]. Available from URL:http:\/\/www.fda.gov\/downloads\/Safety\/MedWatch\/HowToReport\/DownloadForms\/ucm082725.pdf"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1445-5994.2011.02426.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1445-5994.2011.02426.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T09:55:06Z","timestamp":1697363706000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1445-5994.2011.02426.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.1111\/j.1445-5994.2011.02426.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1445-5994.2011.02426.x","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"2011-03-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}